Friday, 06 Dec 2019

You are here

The Global Burden of Rheumatoid Arthritis 2017

The Global Burden of Diseases, Injuries, and Risk Factors study (GBD) from 2017 analyzed the burden of rheumatoid arthritis (RA) for 195 countries between 1990 to 2017 and surmised that RA is a major global public health challenge, with increasing prevalence and incidence rates.

This systematic analysis looked at mortality and morbidity data to estimate prevalence, incidence and disability-adjusted life years (DALYs) from 195 countries, specifically looking at age, sex, socio-demographic Index (SDI; a composite of sociodemographic factors) and Healthcare Access and Quality (an indicator of health system performance) Index.

Globally, the age-standardised point prevalence rate for RA was 246.6 (95% UI 222.4 to 270.8).

The annual incidence rates of RA was 14.9 (95% UI 13.3 to 16.4) in 2017, which increased by 8.2% (95% UI 5.9 to 10.5) from 1990. Yet the RA DALYs per 100 000 population was 43.3 (95% UI 33.0 to 54.5) in 2017, which was a 3.6% lower than the 1990 rate. 

The RA prevalence and DALY rates increased with age and tended to be higher in females; with rates peaking in the 70–74 and 75–79 age groups for females and males, respectively. 

The UK had the highest age-standardised prevalence rate (471.8 (95% UI 428.9 to 514.9)) and age-standardised incidence rate (27.5 (95% UI 24.7 to 30.0)) in 2017.

The growth of RA was highest in Canada, Paraguay and Guatemala with age-standardised prevalence rates (54.7% (95% UI 49.2 to 59.7), 41.8% (95% UI 35.0 to 48.6) and 37.0% (95% UI 30.9 to 43.9), respectively). 

RA remains a significant and growing public health problem requiring programs for earlier detection and publich health strategies to reduce the risk of RA and better monitoring of disease burden.


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Smoking Cessation Lowers RA Disease Activity and CV Risks

A multinational cross-sectional cohort study suggests that smoking cessation in rheumatoid arthritis (RA) patients is associated with lower disease activity measures, improved lipid profiles and lower rates of cardiovascular (CV) events.

Apremilast Reduces Oral Ulcers in Behcet's Syndrome

A multinational trial finds a statistically significant number of patients with Behçet's syndrome showed a greater reduction in the number of oral ulcers with apremilast compared with placebo.

Systemic JIA-Associated Lung Disease

A disease you’ve never heard of is becoming increasingly common and carries a very poor prognosis. 

For me, one of most important aspects of attending the ACR Annual Meeting is to learn about conditions that I don’t know and that may afflict my patients when I return back home. This year’s meeting was no different.

Tapering Of Therapy In RA: Maybe Not So Aggressive Next Time

This ACR has seen some more great work on tapering of therapy in rheumatoid arthritis. It’s a hot topic and one which I get asked about all the time by my patients. Commonly when I start oral csDMARDs patients want to know how long they be will on therapy and that naturally leads to a discussion about what the plan will be in the future about tapering.

ACR 2019 - Report From Day 3 (Tuesday)

Here's my summary of key studies presented Tuesday. 

Tofacitinib in Polyarticular JIA